This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
research:project_proposal_template [2015/02/16 20:45] rkboyce |
research:project_proposal_template [2015/02/16 20:45] (current) rkboyce |
||
|---|---|---|---|
| Line 7: | Line 7: | ||
| **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. | **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. | ||
| - | **Project Lead(s):** Richard D. Boyce, Matthias Samwald, (seeking other collaborators) | + | **Project Lead(s):** Richard D. Boyce, Matthias Samwald, Patrick Ryan, (seeking other collaborators) |
| **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna | **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna | ||